Please Wait...

Alzheimer's & Parkinson's Diseases Congress - AD/PD 2019

March 26, 2019 - 1:00am (EDT) to March 31, 2019 - 1:00am (EDT)

Lisbon, Portugal

Bioclinica's scientific and medical imaging experts deploy advanced imaging techniques in the context of global clinical trials in Alzheimer’s and Parkinson’s Diseases. At this year’s 14th​ International Conference on Alzheimer's and Parkinson's Diseases (ADPD), our scientists are pleased to highlight Bioclinica contributions in oral presentations and scientific posters. Presentations will describe the use of baseline MRI to predict rapid DATscan progression, the importance of centrally reconstructing DATscan SPECT data, and our team’s experience with next-generation Tau tracers. Presentation details below.

Title: Longitudinal progression of DaTscan binding in Parkinson's Disease is associated with reduced regional brain volume at baseline
Authors: David Scott, PhD; Kate Adamczuk, PhD; Nicolas Pannetier, PhD; Mehul Sampat, PhD; Joël Schaerer, PhD; Luc Bracoud, MSc; Joyce Suhy, PhD
Presenter: David Scott, PhD
Session: Symposium 43: Biomarkers, Imaging in PD and LBD 1
Date: March 29


Title: Standardized DAT SPECT reconstruction decreases variance in Striatal Binding Ratios
Authors: Kate Adamczuk,PhD; Chris Conklin, PhD; Luc Bracoud, MSc; Nicolas Pannetier,PhD; Joyce Suhy,PhD; David Scott, PhD
Presenter: Kate Adamczuk, PhD
Date: On display March 27-28


Title: Evaluation of tau deposition in amyloid positive MCI or mild-AD dementia subjects from the elenbecestat MissionAD program using [18F]PI-2620 PET
Authors: Andrew Stephens; Santiago Bullich; Andre Mueller; Mathias Berndt; Susan De Santi; David Scott; Kate Adamczuk; Joyce Suhy; June Kaplow; Stephen Krause; Julia Chang; Bruce Albala; Johan Luthman
Presenters: A joint presentation by LMI, Eisai and Bioclinica 
Date: On display March 27-28

Visit event website



Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @SullyHIT: .@HIMSS writes new definition of interoperability - and seeks feedback @HealthITNews "This definition…
Bioclinica (2 days ago)
RT @DellEMCHealth: Top pharma use cases for the cloud via @HealthITNews #TransformHIT
Bioclinica (2 days ago)
RT @DDNewsOnline: Look into recent efforts to understand & fight #glioblastoma & #medulloblastoma Read our Spotlight on #Oncology “#Cancer…
Bioclinica (2 days ago)
Sponsors conducting clinical trials in #NAFLD or #NASH are invited to join us in an upcoming webinar exploring the…
Bioclinica (2 days ago)
RT @RAPSorg: Reorganization of @US_FDA’s Office of the Commissioner to Begin Soon | #Regulatory Focus #FDA
Bioclinica (2 days ago)
RT @ACROhealth: More than 325 million people own wearable devices, making it more convenient than ever for researchers to incorporate them…
Bioclinica (2 days ago)

Latest Blogs:

Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box